Clinical Trials Directory

Trials / Completed

CompletedNCT03674476

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986036 in Participants With Varying Degrees of Renal Function

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
21 Years – 75 Years
Healthy volunteers
Accepted

Summary

This is an investigational study to evaluate the experimental medication BMS-986036 in participants with different levels of kidney function.

Conditions

Interventions

TypeNameDescription
DRUGBMS-986036Specified dose on specified days

Timeline

Start date
2018-09-11
Primary completion
2019-06-24
Completion
2019-06-24
First posted
2018-09-17
Last updated
2019-10-08

Locations

4 sites across 2 countries: Czechia, Hungary

Regulatory

Source: ClinicalTrials.gov record NCT03674476. Inclusion in this directory is not an endorsement.